INTRODUCTION: The factor XIII Val34Leu (100 G-->T) and beta-fibrinogen Hae III (-455 G-->A) gene variants have been associated with reduced risk of venous thrombosis, but not in all studies. METHODS: We investigated the associations of these polymorphisms with risk of venous thrombosis in a prospective, population-based study of 21,680 men and women aged 45-100 years at enrollment. Factor XIII 100 G/T and beta-fibrinogen -455 G/A were analyzed on stored DNA from 511 thrombosis cases and 1028 control subjects without thrombosis during follow up. RESULTS: The beta-fibrinogen A allele was present in 24.4% of cases and 32.3% of controls. Compared to GG subjects, the age, race, and sex adjusted odds ratio (OR) of venous thrombosis was 0.77 (95% CI 0.59-0.99) for GA subjects, and 0.60 (95% CI 0.31-1.16) for AA subjects. The adjusted OR of thrombosis associated with factor XIII 100 G/T was 1.01 (95% CI 0.81-1.26) for GT subjects and 0.45 (95% CI 0.44-1.19) for TT subjects, compared to GG. For both genotypes, ORs of thrombosis were similar in whites and non-whites, although there were no non-white fibrinogen AA cases. beta-fibrinogen -455 GA or AA attenuated the thrombosis risk associated with obesity (from 2.14 to 1.25) and factor V Leiden (from 3.89 to 2.36). CONCLUSIONS: beta-fibrinogen -455 G/A, but not factor XIII 100 G/T, was associated with a lower risk of venous thrombosis in this general population sample. beta-fibrinogen -455 A may attenuate the increased thrombosis risk associated with obesity or factor V Leiden.
INTRODUCTION: The factor XIII Val34Leu (100 G-->T) and beta-fibrinogen Hae III (-455 G-->A) gene variants have been associated with reduced risk of venous thrombosis, but not in all studies. METHODS: We investigated the associations of these polymorphisms with risk of venous thrombosis in a prospective, population-based study of 21,680 men and women aged 45-100 years at enrollment. Factor XIII 100 G/T and beta-fibrinogen -455 G/A were analyzed on stored DNA from 511 thrombosis cases and 1028 control subjects without thrombosis during follow up. RESULTS: The beta-fibrinogen A allele was present in 24.4% of cases and 32.3% of controls. Compared to GG subjects, the age, race, and sex adjusted odds ratio (OR) of venous thrombosis was 0.77 (95% CI 0.59-0.99) for GA subjects, and 0.60 (95% CI 0.31-1.16) for AA subjects. The adjusted OR of thrombosis associated with factor XIII 100 G/T was 1.01 (95% CI 0.81-1.26) for GT subjects and 0.45 (95% CI 0.44-1.19) for TT subjects, compared to GG. For both genotypes, ORs of thrombosis were similar in whites and non-whites, although there were no non-white fibrinogen AA cases. beta-fibrinogen -455 GA or AA attenuated the thrombosis risk associated with obesity (from 2.14 to 1.25) and factor V Leiden (from 3.89 to 2.36). CONCLUSIONS: beta-fibrinogen -455 G/A, but not factor XIII 100 G/T, was associated with a lower risk of venous thrombosis in this general population sample. beta-fibrinogen -455 A may attenuate the increased thrombosis risk associated with obesity or factor V Leiden.
Authors: U Wartiovaara; H Mikkola; G Szôke; G Haramura; L Kárpáti; I Balogh; R Lassila; L Muszbek; A Palotie Journal: Thromb Haemost Date: 2000-10 Impact factor: 5.249
Authors: I Balogh; G Szôke; L Kárpáti; U Wartiovaara; E Katona; I Komáromi; G Haramura; G Pfliegler; H Mikkola; L Muszbek Journal: Blood Date: 2000-10-01 Impact factor: 22.113
Authors: H Austin; W C Hooper; C Lally; A Dilley; D Ellingsen; C Wideman; N K Wenger; P Rawlins; V Silva; B Evatt Journal: J Clin Epidemiol Date: 2000-10 Impact factor: 6.437
Authors: Aaron R Folsom; Mary Cushman; Michael Y Tsai; Nena Aleksic; Susan R Heckbert; Lori L Boland; Albert W Tsai; N David Yanez; Wayne D Rosamond Journal: Blood Date: 2002-04-15 Impact factor: 22.113
Authors: Astrid Van Hylckama Vlieg; Nantarat Komanasin; Robert A S Ariëns; Swibertus R Poort; Peter J Grant; Rogier M Bertina; Frits R Rosendaal Journal: Br J Haematol Date: 2002-10 Impact factor: 6.998